Call Options

14 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2022

Oct 25, 2022

SELL
$273.83 - $305.53 $8.08 Million - $9.01 Million
-29,500 Reduced 98.66%
400 $2,000
Q2 2022

Aug 04, 2022

SELL
$234.96 - $292.55 $4.44 Million - $5.53 Million
-18,900 Reduced 38.73%
29,900 $2.43 Million
Q1 2022

Apr 14, 2022

BUY
$221.42 - $260.97 $5.6 Million - $6.6 Million
25,300 Added 107.66%
48,800 $2.25 Million
Q4 2021

Jan 18, 2022

BUY
$177.01 - $223.45 $3.89 Million - $4.92 Million
22,000 Added 1466.67%
23,500 $1.06 Million
Q1 2021

Apr 26, 2021

BUY
$207.02 - $241.31 $82,808 - $96,524
400 Added 36.36%
1,500 $11,000
Q3 2019

Oct 28, 2019

BUY
$166.23 - $187.09 $16,623 - $18,709
100 Added 10.0%
1,100 $16,000
Q2 2019

Aug 09, 2019

SELL
$164.61 - $190.37 $1.12 Million - $1.29 Million
-6,800 Reduced 87.18%
1,000 $21,000
Q1 2019

May 10, 2019

SELL
$163.73 - $194.7 $1.03 Million - $1.23 Million
-6,300 Reduced 44.68%
7,800 $4,000
Q4 2018

Feb 05, 2019

SELL
$151.91 - $192.21 $121,528 - $153,768
-800 Reduced 5.37%
14,100 $82,000
Q3 2018

Nov 07, 2018

SELL
$167.73 - $192.74 $83,865 - $96,370
-500 Reduced 3.25%
14,900 $291,000
Q2 2018

Aug 10, 2018

SELL
$145.72 - $169.96 $1.92 Million - $2.24 Million
-13,200 Reduced 46.15%
15,400 $235,000
Q1 2018

May 11, 2018

SELL
$151.6 - $177.13 $3.05 Million - $3.56 Million
-20,100 Reduced 41.27%
28,600 $349,000
Q4 2017

Jan 17, 2018

SELL
$137.28 - $155.55 $5.45 Million - $6.18 Million
-39,700 Reduced 44.91%
48,700 $542,000
Q3 2017

Oct 17, 2017

BUY
$148.13 - $162.24 $13.1 Million - $14.3 Million
88,400
88,400 $1.32 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.